TME Pharma N.V., a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer, has announced a collaboration with medical data analytics company, aimed analytics.
The partnership aims to leverage AI to create new and improved drug candidates without the need for time and resource-intensive laboratory testing.
The collaboration leverages recent advances in AI to accelerate timelines while reducing associated costs and need for experimental infrastructure.
TME Pharma CEO, Aram Mangasarian, said: “The 2024 Nobel Prize in Chemistry was awarded for AI-based models that allow remarkable prediction of molecular structures.
“This technology can also be used to discover new drugs and improved versions of existing drugs.
“The goal of this collaboration is to allow TME Pharma to not only bring its existing drugs to the table for strategic partners, but also the potential for rapid and efficient discovery of new drugs.”
TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. 
The company’s oncology-focused pipeline is designed to act on the tumour microenvironment (TME) and the cancer immunity cycle by breaking tumour protection barriers against the immune system and blocking tumour repair.
aimed analytics, is an AI-based data analytics company aiming to advance innovation in pharmaceutical research and development with its data analytics platform and application of advanced deep-learning models for structural prediction.
By integrating cutting-edge AI technologies with expertise in omics data analysis, aimed analytics aims to empower researchers to uncover insights that accelerate drug discovery and development
aimed analytics CEO, Dr Patrick Günther, said: “We are excited to partner with TME Pharma and contribute our deep-learning and structural modelling expertise to their innovative approach in cancer treatment,.
“By enabling a comprehensive search for promising therapeutic compounds and bringing a new level of technological sophistication to TME Pharma’s drug discovery efforts, we aim to accelerate the discovery of more effective treatments and potentially lead to breakthrough therapies for patients in need.”
